Ser535
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser535  -  SIRT1 (human)

Site Information
PPtPLHVsEDsssPE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 4770103
Available spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 )
Disease tissue studied:
lung cancer ( 1 , 2 , 3 , 4 , 5 , 7 ) , non-small cell lung cancer ( 1 , 2 , 3 , 5 , 7 ) , non-small cell lung adenocarcinoma ( 1 , 2 , 3 , 4 , 5 ) , non-small cell large cell lung carcinoma ( 2 ) , non-small cell squamous cell lung carcinoma ( 4 )
Relevant cell line - cell type - tissue:
293E (epithelial) ( 6 ) , A549 (pulmonary) ( 1 ) , Calu-3 (pulmonary) ( 3 ) , DMS153 (pulmonary) ( 5 ) , ES (stem) ( 9 ) , HCC15 (pulmonary) ( 4 ) , HCC827 (pulmonary) ( 3 ) , Jurkat (T lymphocyte) ( 8 ) , LOU-NH91 (squamous) ( 4 ) , lung ( 1 , 2 , 3 , 4 , 5 , 7 ) , NCI-H1299 (pulmonary) ( 2 ) , NCI-H1355 (pulmonary) ( 1 ) , NCI-H1437 (pulmonary) ( 5 ) , NCI-H1650 (pulmonary) ( 3 ) , NCI-H1703 (squamous) ( 4 ) , NCI-H1734 (pulmonary) ( 2 ) , NCI-H1792 (pulmonary) ( 1 ) , NCI-H1944 (pulmonary) ( 2 ) , NCI-H1975 (pulmonary) ( 3 ) , NCI-H2073 (pulmonary) ( 4 , 5 ) , NCI-H209 (pulmonary) ( 5 ) , NCI-H2106 (pulmonary) ( 3 ) , NCI-H23 (pulmonary) ( 1 ) , NCI-H2342 (pulmonary) ( 4 ) , NCI-H358 (pulmonary) ( 2 ) , NCI-H441 (pulmonary) ( 1 ) , NCI-H460 (pulmonary) ( 2 ) , NCI-H838 (pulmonary) ( 5 )

References 

1

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

2

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

3

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

4

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

5

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

6

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

7

Rikova K (2010) CST Curation Set: 9455; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

8

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

9

Sasaki T, et al. (2008) Phosphorylation regulates SIRT1 function. PLoS One 3, e4020
19107194   Curated Info